Pressure BioSciences Inc.  (PBIO) Trade Now »     Rate PBIO  -  Discuss PBIO  -  Add to Watch List        

Home

Analysis & Videos

Quotes

Bull or Bear

Discuss

PBIO Analysis & Videos »


PBIO: Bull or Bear?

Under the Radar Healthcare Stocks: Protox, Pressure BioSciences, Unilife PBIO

73%

+0.00% in 1 day Below are three under the radar stocks from the healthcare sector that I have been following for the past 3-6 months which have upcoming catalysts in the form of expected strategic deals, clinical trial results, and other corporate developments.  Click here to check out my <font> kaChing.com virtual investing portfolio </font> , strategy, long / short virtual stock picks, and statistics since I started using the site in mid-April.   <> <font> Protox Therapeutics (TSX: PRX.TO) (OTC: PTXRF.PK) </font> (click on preceding link for the Company’s ProActive News Room landing<><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><>... Continue reading »

By  Mike Havrilla   (+1.04%  risk: conservative)  11/24/09

Comment

Pressure BioSciences (NASDAQ: PBIO): A New Paradigm for Sample Processing PBIO

73%

-9.46% in 66 days (closed on 11/24/09) <> <> Pressure BioSciences (NASDAQ: PBIO) is a life science research tools company that is commercializing and developing its innovative core technology platform known as pressure cycling technology (PCT). PCT uses cycles of hydrostatic (water-based) pressure between ambient and ultra-high levels (up to 45,000 PSI) at controlled temperatures to rapidly and repeatedly control interactions at the molecular level. The Company sells and installs pressure-generating instruments (Barocyclers), and its internally developed consumables product line includes PULSE (Pressure Used to Lyse Samples for Ext... Continue reading »

By  Mike Havrilla   (+1.04%  risk: conservative)  09/19/09

2 comments

Pressure BioSciences Inc. PBIO

62%

-52.14% in 509 days Pressure BioSciences, Inc., a life sciences company, engages in the research, development, and commercialization of pressure cycling technology (PCT) that uses cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions. The company offers Barocycler instrumentation, which includes Barocycler NEP3229 that is capable of processing up to three samples simultaneously using its single-use PULSE Tubes; and Barocycler NEP2320, which processes one sample at a time and works on compressed air. It also provides consumable products comprising PULSE Tubes... Continue reading »

By  Marian Filo   (-24.55%  risk: aggressive)  07/03/08

Comment

Pressure BioSciences Inc. (PBIO) Hires Matthew Potter to Join Management Team as the Vice President of Sales PBIO

66%

-75.00% in 257 days (closed on 11/24/08) Today Pressure BioSciences Incorporated announced that it has added a new member to its senior executive management team; Vice President of Sales. Matthew B. Potter will now oversee Pressure Biosciences’ seven US-based, regional sales directors and will be responsible for driving the Company’s commercialization of their novel and patented pressure cycling technology (PCT) product line. Matthew Potter brings just short of twenty years of sales and management experience in both the pharmaceutical and biotechnology fields. Potter has been a Sales Manager at Pharmacia Biotech; Nation... Continue reading »

By  quality stocks   (-17.54%  risk: moderate)  03/12/08

Comment

Pressure Biosciences, Inc. (PBIO) - Equipped with Product Line to Fight Disease PBIO

66%

-3.85% in 6 days (closed on 03/12/08) Founded in 1978, Pressure Biosciences (NASDAQ: PBIO) began significant operations in 1986 and went public 10 years later in 1996, under its former name, Boston Biomedica, Inc. Today the company holds 13 U.S. patents and four foreign patents for applications of its Pressure Cycling Technology (PCT), used in the healthcare field for genomics, proteomics and nucleic acid testing with the ability to rupture cells to release significantly more proteins in fatty tissue. The company’s PCT Sample Preparation System (PCT SPS) allows for the safe, rapid and reproducible extraction of DNA, RNA,< />< />< />< />< />< />... Continue reading »

By  quality stocks   (-17.54%  risk: moderate)  03/06/08

Comment

Expanded Sales Force Earns Pressure BioSciences, Inc. (PBIO) a “Speculative Strong Buy” Rating and Increased Sales PBIO

66%

-3.26% in 8 days (closed on 03/06/08) Dutton Associates recently rated Pressure BioSciences, Inc. (NASDAQ: PBIO) as a “Speculative Strong Buy,” pricing the 12-month target at $10 per share. The research report commends the company on its “unique and superior technology” applicable to a variety of areas in the life-sciences field. As Pressure BioSciences utilizes its expanded sales force, Dutton said it expects sales to increase in the upcoming quarters of 2008. The company’s Commercialization Plan called for the addition of seven full-time sales directors to help the company spread its regional coverage. ... Continue reading »

By  quality stocks   (-17.54%  risk: moderate)  02/27/08

Comment

Pressure Biosciences, Inc. (PBIO) Rolls Out New ProteoSolveLRS Kit to Battle Obesity PBIO

66%

+0.94% in 12 days (closed on 02/27/08) According to the most recent National Health and Nutrition Examination survey, roughly two-thirds of the adults in the United States are overweight, slowly closing the gap between themselves and the one-third of Americans considered obese. Analyzing the protein from lipid-rich tissues helps researchers understand the disease that kills about 300,000 people each year in the U.S. Additionally, obesity is linked to heart disease, stroke, cancer and diabetes. PressureBiosciences, Inc. (NASDAQ: PBIO) developed Pressure Cycling Technology (PCT) which uses cycles of hydrostatic pressure, as... Continue reading »

By  quality stocks   (-17.54%  risk: moderate)  02/15/08

Comment

People Bullish on PBIO

Mike Havrilla Principal 73% 1 day ago

Marian Filo Principal 62% about 1 year ago

Johns Wu Associate 47% over 3 years ago

People Bearish on PBIO

jpcoombs Analyst 51% over 2 years ago

crispy Sr. Associate 74% over 3 years ago

... more »  

None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.